Drug Type T-lymphocyte cell therapy |
Synonyms HA1 TCR CD8+ CD4+ Tm Cells, HA1 TCR T Cells, HA1TCR2 |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Phase 1 | United States | 05 Feb 2018 |